These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29285035)

  • 61. Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer.
    Zhou D; Ouyang Q; Liu L; Liu J; Tang Y; Xiao M; Wang Y; He Q; Hu ZY
    Transl Oncol; 2019 May; 12(5):764-774. PubMed ID: 30893632
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.
    Almstedt K; Schmidt M
    Breast Care (Basel); 2015 Jul; 10(3):168-72. PubMed ID: 26557821
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
    Stringer EM; Fleming GF
    Eur Endocrinol; 2013 Mar; 9(1):18-21. PubMed ID: 30349605
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predicting clinical response to everolimus in ER+ breast cancers using machine-learning.
    Nath A; Cosgrove PA; Chang JT; Bild AH
    Front Mol Biosci; 2022; 9():981962. PubMed ID: 36304922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.
    Arora S; Akhil R; Chacko RT; George R
    Indian J Med Paediatr Oncol; 2016; 37(2):116-8. PubMed ID: 27168711
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A review of the endocrine resistance in hormone-positive breast cancer.
    Chien TJ
    Am J Cancer Res; 2021; 11(8):3813-3831. PubMed ID: 34522451
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma.
    Pilling A; Wee C; Bar-Meir E; Dyson G; Hwang O; Gupta N; Chitale D; Hwang C
    Case Rep Oncol; 2021; 14(2):1194-1200. PubMed ID: 34703436
    [TBL] [Abstract][Full Text] [Related]  

  • 68. mTOR inhibition in management of advanced breast cancer.
    Nag S
    Indian J Med Paediatr Oncol; 2012 Apr; 33(2):89-94. PubMed ID: 22988350
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
    Cappelletti MR; Gnetti L; Santini D; Spada D; Fox SB; Generali D
    Oncoscience; 2015; 2(6):567-9. PubMed ID: 26244161
    [No Abstract]   [Full Text] [Related]  

  • 70. Clinical Observation of Improved Outcomes of Patients With
    Anderson MR; Denson AC; Zaman S; Han HS; Soliman HH
    JCO Precis Oncol; 2018 Nov; 2():1-5. PubMed ID: 35135142
    [No Abstract]   [Full Text] [Related]  

  • 71. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
    Reinert T; Barrios CH
    Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
    Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
    J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer.
    Li Y; Du W; Yang R; Wei X; Li H; Zhang X
    Clin Med Insights Oncol; 2024; 18():11795549231219239. PubMed ID: 38187458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer.
    Yuan J; Yang L; Li Z; Zhang H; Wang Q; Huang J; Wang B; Mohan CD; Sethi G; Wang G
    Front Endocrinol (Lausanne); 2023; 14():1261283. PubMed ID: 37900137
    [TBL] [Abstract][Full Text] [Related]  

  • 75. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
    Fukuoka S; Koga Y; Yamauchi M; Koganemaru S; Yasunaga M; Shitara K; Doi T; Yoshino T; Kuronita T; Elenbaas B; Wahra P; Zhang H; Crowley L; Jenkins MH; Clark A; Kojima T
    Sci Rep; 2023 Sep; 13(1):16017. PubMed ID: 37749105
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
    Bhin J; Yemelyanenko J; Chao X; Klarenbeek S; Opdam M; Malka Y; Hoekman L; Kruger D; Bleijerveld O; Brambillasca CS; Sprengers J; Siteur B; Annunziato S; van Haren MJ; Martin NI; van de Ven M; Peters D; Agami R; Linn SC; Boven E; Altelaar M; Jonkers J; Zingg D; Wessels LFA
    J Exp Med; 2023 Nov; 220(11):. PubMed ID: 37642941
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer.
    Aktas B; Fehm TN; Welslau M; Müller V; Lüftner D; Schütz F; Fasching PA; Janni W; Thomssen C; Witzel I; Belleville E; Untch M; Thill M; Tesch H; Ditsch N; Lux MP; Banys-Paluchowski M; Kolberg-Liedtke C; Hartkopf AD; Wöckel A; Kolberg HC; Stickeler E; Harbeck N; Schneeweiss A
    Geburtshilfe Frauenheilkd; 2022 Sep; 82(9):922-931. PubMed ID: 36110891
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy.
    Cuellar-Vite L; Weber-Bonk KL; Abdul-Karim FW; Booth CN; Keri RA
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
    Schettini F; Sobhani N; Ianza A; Triulzi T; Molteni A; Lazzari MC; Strina C; Milani M; Corona SP; Sirico M; Bernocchi O; Giudici F; Cappelletti MR; Ciruelos E; Jerusalem G; Loi S; Fox SB; Generali D
    Breast Cancer Res Treat; 2020 Nov; 184(2):421-431. PubMed ID: 32770287
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
    Kruger DT; Opdam M; van der Noort V; Sanders J; Nieuwenhuis M; de Valk B; Beelen KJ; Linn SC; Boven E
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3013-3023. PubMed ID: 32566979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.